UTHR · NASDAQ · STOCK
United Therapeutics (UTHR) Stock Analysis
$549.32
52W $409.07 – $609.35
60/100
$23.31B
18.2
0.56
⚠
Buy rating, but near-term risk/reward is unfavorable
The long-term recommendation is based on the composite investment score. The near-term risk/reward is based on nearby support and resistance levels. These can differ when a strong company trades close to resistance with support further below.
Is UTHR Bullish or Bearish?
Bullish.
Innellis AI committee rates United Therapeutics (UTHR) Buy with a composite score of 60/100
, based on 6 analysts with 67% agreement.
Last updated October 10, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +14.99 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -5.01 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The primary driver is roe of 20.2% shows genuine earnings power backing the valuation. The main limiting factor is sector concentration is already high (hhi 2796.97). The committee is constructive but not yet at full conviction.
Bull & Bear Case
Bull Case
- ROE of 20.2% shows genuine earnings power backing the valuation — Value
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock — Risk
Bear Case
- Price structure (LH_LL) contradicts the uptrend -- mixed signals — Technical
- Bollinger bandwidth of 22.8% signals elevated volatility — Risk
- News sentiment is negative (-0.27 across 41 articles, 14d) — News
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 10, 2026
Overall Committee Score
60/100
Agreement
67%
Analysts
6
Conviction
Moderate
Sector Rank
Top 32%
of 192 Healthcare peers
Value Analyst
bullish
65
/ 100 · High confidence
Classic value case: cheap on multiples with earnings power to back it up
+ ROE of 20.2% shows genuine earnings power backing the valuation
Growth Analyst
bullish
62
/ 100 · Moderate confidence
Strong, accelerating growth with consistent execution
+ Quarter-over-quarter growth rate is ACCELERATING, not just positive
Technical Analyst
bullish
61
/ 100 · High confidence
Price action is constructive -- trend and momentum agree
+ Price structure making higher highs and higher lows
− Price structure (LH_LL) contradicts the uptrend -- mixed signals
Risk Analyst
neutral
58
/ 100 · Moderate confidence
Moderate risk -- no single red flag, but nothing that clearly de-risks the position either
+ Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock
− Bollinger bandwidth of 22.8% signals elevated volatility
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
neutral
49
/ 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
− News sentiment is negative (-0.27 across 41 articles, 14d)
Portfolio Manager
bearish
30
/ 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Investment Thesis Evolution
Committee score moved marginally from 60.0 to 60.0.
- New bearish signals: 2 appeared.
- Bearish pressure eased: 2 signal(s) disappeared.
Analyst-level changes:
- News Analyst: +1 bearish signal(s).
- Risk Analyst: +1 bearish signal(s).
Comparing 2026-10-09 to 2026-10-10 (1 day apart).
Technical Analysis
RSI (14)
62.9
Neutral
MACD Histogram
5.296
Bullish Momentum
Trend Direction
Uptrend
Weekly: Sideways
Market Structure
Lh Ll
Support
$458.18
Resistance
$563.49
Bollinger %B
0.82
Inside Bands
Price vs Moving Averages
EMA 9
$534.03
Above
EMA 21
$521.07
Above
EMA 50
$518.18
Above
EMA 200
$508.42
Above
Fundamental Analysis
Valuation
68
Growth
60
Profitability
99
Financial Health
100
Cash Flow
70
Valuation
P/E Ratio
18.2×
P/B Ratio
3.66×
PEG Ratio
2.00
Dividend Yield
0.00%
52W High
$609.35
52W Low
$409.07
Quality & Growth
ROE
1880.9%
ROA
1693.8%
Gross Margin
8614.0%
Operating Margin
4448.9%
Revenue Growth YoY
—
Debt / Equity
0.00
AI Fundamental Assessment
P/E ratio of 18.2 (inexpensive relative to a 15-40x range); Price-to-book of 3.7x; PEG ratio of 2.0 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 18.8%; Return on assets of 16.9%; Net margin of 41.6%; Gross margin of 86.1%; Current ratio of 5.73 (healthy short-term liquidity); Debt-to-equity of 0.00; Free cash flow per share is positive (25.66); Most recent quarter beat estimates by 4.3%; EPS growth accelerating (-24.4% -> +24.9% QoQ); Average YoY EPS growth of 13.4%; Analyst estimates falling over recent quarters
Get the Full UTHR Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →